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Abstract
Introduction: Perioperative intravesical chemotherapy (IVC) at or around the time of radical nephroureterectomy (RNU) reduces the
risk of intravesical recurrence. Guidelines since 2013 have recommended its use. The objective of this study is to examine IVC utilization
and determine predictors of its administration within a large international consortium.
Methods and materials: Data was collected from 17 academic centers on patients who underwent robotic/laparoscopic RNU between
2006 and 2020. Patients who underwent concomitant radical cystectomy and cases in which IVC administration details were unknown were
excluded. Univariate and multivariate analyses were utilized to determine predictors of IVC administration. A Joinpoint regression was performed to evaluate utilization by year.

*Corresponding author. Tel.: 214-645-8765; fax: 214-648-8786.
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Results: Six hundred and fifty-nine patients were included. A total of 512 (78%) did not receive IVC while 147 (22%) did. Non-IVC
patients were older (P < 0.001), had higher ECOG scores (P = 0.003), and had more multifocal disease (23% vs. 12%, P = 0.005). Those in
the IVC group were more likely to have higher clinical T stage disease (P = 0.008), undergone laparoscopic RNU (83% vs. 68%, P <
0.001), undergone endoscopic management of the bladder cuff (20% vs. 4%, P = 0.008). Multivariable regression showed that decreased
age (OR 0.940, P < 0.001), laparoscopic approach (OR 2.403, P = 0.008), and endoscopic management of the bladder cuff (OR 7.619, P <
0.001) were significant predictors favoring IVC administration. Treatment at a European center was associated with lower IVC use (OR
0.278, P = 0.018). Overall utilization of IVC after the 2013 European Association of Urology (EAU) guideline was 24% vs. 0% prior to
2013 (P < 0.001). Limitations include limited data regarding IVC timing/agent and inclusion of minimally invasive RNU patients only.
Conclusions: While IVC use has increased since being added to the EAU UTUC guidelines, its use remains low at academic centers,
particularly within Europe. Ó 2022 Elsevier Inc. All rights reserved.

Keywords: Upper tract urothelial carcinoma; Intravesical chemotherapy; Nephroureterectomy; Practice trends

1. Introduction
Intravesical recurrence of urothelial cell carcinoma (UCC)
occurs in 22% to 47% of patients with upper tract urothelial
carcinoma [1]. Multiple mechanisms of pathogenesis have
been proposed. Evidence of monoclonal mutations possessed
by both the upper tract and metachronous bladder cancers
suggest that individual cells from the primary tumor may
seed additional foci [2−4]. Additional observations may further suggest that surgical manipulation directly disrupts the
primary tumor, leading to lower tract seeding [5,6]. Some
evidence additionally supports that certain surgical
techniques may impart a higher risk of intravesical recurrence [7,8]. On the other hand, conflicting evidence of oligoclonal metachronous bladder tumors supports a pathogenesis
related to long-term, whole field exposure to carcinogenic
agents [9,10]. More recent evidence has suggested that both
proposed mechanisms are likely at play [11].
Due to the apparently linked pathogenesis between
upper tract urothelial carcinoma and intravesical recurrence, a number of studies have investigated the use of
intravesical chemotherapy in the post radical-nephroureterectomy (RNU) setting. ODMIT-C, a prospective, multicenter randomized control trial demonstrated an 11% absolute
risk reduction and 40% relative risk reduction with a single
postoperative dose of intravesical mitomycin C following
nephroureterectomy [12]. Ito et al. similarly demonstrated
an effect on bladder recurrence with single-dose intravesical pirarubicin and found the absolute risk reduction to be
even greater at 2 years after RNU (17% at 1 year, 25% at
2 years) [13].
The 2013 European Association of Urology (EAU)
guidelines introduced single-dose postoperative instillation
of intravesical chemotherapy as a level B recommendation
[14] and this recommendation remains in the present-day
EAU guidelines (now as level 1 recommendation), with the
highest level of evidence of any of the management guidelines. This recommendation was subsequently added to the
National Comprehensive Cancer Network guidelines in
2017 [15]. Little is known about utilization patterns of perioperative single-dose intravesical chemotherapy and its

utilization has been proposed as a quality metric for highquality UTUC care [16].
Given level-1 data supporting efficacy of this treatment,
we sought to better define practice patterns around its use.
2. Methods and materials
The ROBUUST collaborative is a shared database
among 17 tertiary care hospitals worldwide (10 United
States, 4 Europe, 2 Asia) including patients who underwent
minimally invasive (robotic or laparoscopic) RNU between
2006 and 2020. Demographic, pathologic, surgical, and follow-up data are included in the dataset.
Patients with prior or concomitant cystectomy were
excluded. Those with unknown information regarding perioperative IVC treatment were also excluded from analysis.
Univariate analysis was performed to detect differences
between those who did not receive IVC treatment and those
who did. Use of IVC was tabulated across study years. A
multivariable logistic regression was conducted to evaluate
for predictors of receipt of IVC. SPSS version 25 (IBM
Corporation, Armonk, NY) was utilized for statistical analysis with the significance set at P < 0.05. A Joinpoint regression analysis using Joinpoint Trend Analysis Software
Version 4.9.0.0 (National Cancer Institute, Bethesda, MD).
3. Results
Eight hundred seventy patients underwent minimally
invasive RNU and were included in the dataset. A total 40
of these patients underwent prior cystectomy and an additional 89 received concomitant cystectomy. Eighty-two did
not have data available regarding intravesical chemotherapy treatment. Overall, 659 patients were included in our
analysis. Baseline characteristics are shown on Table 1.
Among the 659, 512 (78%) did not receive IVC, while
147 (22%) did. Patients in the non-IVC group were older,
71.6 vs. 67.9 (P < 0.001). Non-IVC patients were also
noted to be less healthy, with 63% being ECOG 3 vs. 47%
in the IVC group (P = 0.003). They were also more likely to
have multifocal disease (23% vs. 12%, P = 0.005). Those
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Table 1
Baseline characteristics
n = 659

n
Age
Gender
Male
Female
Race
Caucasian
Black
Hispanic
Asian
Other
BMI
ECOG
1
2
3
cT
Ta/T1
T2-T4
Multifocality
No
Yes
Prior ureteroscopy
No
Yes
Neoadjuvant chemotherapy
No
Yes
Bladder cuff
Excision
Endoscopic
Surgical approach
Robotic
Laparoscopic
Robo/Lap converted
Region
USA
Europe
Asia
Median length of stay (IQR)
30-d readmit
No
Yes
a

No IVC

IVC

Pa

512
71.6

147
67.9

<0.001

330 (64.5)
182 (35.5)

94 (63.9)
53 (36.1)

0.910

338 (75.4)
28 (6.3)
23 (5.1)
48 (10.7)
11 (2.5)
27.3

77 (53.1)
5 (3.4)
12 (8.3)
49 (33.8)
2 (1.4)
27.4

<0.001

15 (3.4)
150 (33.6)
282 (63.1)

7 (4.9)
69 (48.3)
67 (46.9)

0.003

279 (72.7)
105 (27.3)

77 (60.2)
51 (39.8)

0.008

381 (77.1)
113 (22.9)

129 (87.8)
18 (12.2)

0.005

155 (31.3)
341 (68.8)

35 (24.8)
106 (75.2)

0.141

475 (92.8)
37 (7.2)

141 (95.9)
6 (4.1)

0.174

468 (96.1)
19 (3.9)

111 (79.9)
28 (20.1)

<0.001

424 (82.8)
74 (14.5)
14 (2.7)

98 (67.6)
47 (32.4)
0 (0.0)

<0.001

347 (78.7)
133 (91.1)
32 (44.4)
4 (2-6)

94 (21.3)
13 (8.9)
40 (55.6)
4 (3-6)

<0.001

482 (94.9)
26 (5.1)

140 (95.9)
6 (4.1)

Fig. 1. Utilization of perioperative IVC over time.

0.823

0.722
0.619

Bold values denote statistical significance at the p < 0.05 level.

who did not receive IVC were more likely to have undergone a robotic, rather than laparoscopic RNU (83% vs.
68%, P < 0.001). Patients in the IVC group were disproportionately likely to be Asian (34% vs. 11%, P < 0.001).
Among those treated at US centers, 21% received IVC, as
compared with 9% at European sites and 56% at Asian
institutions (P < 0.001). Those who received IVC had
higher clinical stage disease (40% cT2-4 vs. 27%,
P = 0.008). Patients in the IVC group were more likely to
have undergone endoscopic management of the bladder
cuff than those in the non-IVC group (20% vs. 4%, P <
0.001). There were no significant differences between prior

use of ureteroscopy or neoadjuvant chemotherapy between
the IVC and non-IVC groups. There were also no differences between median length of stay or 30-day readmission
rates between the groups.
The utilization of IVC is noted in Fig. 1. No patients
received IVC prior to 2014. In 2014, 7/82 (9%) of patients
received IVC. This increased to 23/104 (22%) in 2015,
but again declined in 2016 to 15%. In 2017 31/132 (23%)
received IVC and a roughly similar number 29/134 (22%)
underwent this therapy in 2018. Incompletely collected
data from 2019 indicates a possible uptick in utilization,
40/59 (68%). Joinpoint regression indicated a trend in
annual growth of 8% between 2013 and 2019 (P = 0.02).
There was noted to be variability in institutional usage of
IVC, with a range of 0% utilization (7 centers) to 93% utilization at one center (mean 19.9%, standard deviation
31.8%). Only 3 centers reported usage with >50% of
cases.
On multivariable analysis (Table 2), older age was associated with a lower utilization of IVC (OR 0.940, P <
0.001). The geographic location of the center was independently associated with IVC use, as those treated in European centers were less likely to receive IVC (OR 0.278,
P = 0.018). The years 2014 to 2017 were associated with
lower utilization of IVC relative to 2018 to 2020 (OR
0.547, P = 0.025). Laparoscopic approach was associated
with receipt of IVC (OR 2.403, P = 0.008), as did endoscopic management of the bladder cuff (OR 7.619, P <
0.001). While not explicitly noted in Table 1, patients who
underwent a laparoscopic RNU were far more likely to
undergo endoscopic management of the bladder cuff than
those who underwent robotic RNU (45% vs. 17%, P <
0.001). There was a trend toward decreased utilization of
IVC among those who had received neoadjuvant chemotherapy (OR 0.320, P = 0.072).

4. Discussion
This study demonstrated low rates of utilization of perioperative intravesical chemotherapy at the time of RNU.
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Table 2
Multivariable regression: predictors of IVC administration

Age
ECOG
1
2
3
Race
Caucasian
Black
Hispanic
Asian
Other
Surgery Year
2018−2020
2014−2017
2006−2013
cT
cTa/Tis/T1
cT2-4
Multifocal
No
Yes
NAC
No
Yes
Prior URS
No
Yes
Region
USA
Europe
Asia
Surgical approach
Robotic
Laparoscopic
Robotic/Lap converted
Bladder cuff
Excision
Endoscopic

OR

95% CI

P

0.940

0.913−0.967

<0.001

−
0.774
0.522

−
0.206−2.912
0.134−2.036

−
0.705
0.349

−
0.499
1.251
1.722
0.459

−
0.121−2.054
0.434−3.610
0.532−5.577
0.054−3.929

−
0.335
0.678
0.365
0.477

−
0.458
0.000

−
0.264−0.793
0.000

−
0.005
0.998

−
0.729

−
0.365−1.455

−
0.370

−
0.734

−
0.364−1.480

−
0.387

−
0.320

−
0.092−1.107

−
0.072

−
1.242

−
0.622−2.477

−
0.539

−
0.278
1.522

−
0.096−0.804
0.393−5.893

−
0.018
0.543

−
2.403
0.000

−
1.260−4.584
0.000

−
0.008
0.999

−
7.619

−
3.530−16.445

−
<0.001

This is one of very few studies to examine utilization patterns of IVC from clinical data.
Across the centers that contribute to our aggregate data,
the recorded administration rate of IVC after 2013 (when
the EAU guidelines were updated) was 24%. This is
markedly lower than the estimate of 51% acquired from
self-report survey data from Lu et al. [17], although somewhat favorable relative to a survey of Japanese urologists,
which estimated usage at 10.5% [18]. Utilization of IVC is
surprisingly low considering the extent of its benefit. While
its usage appears to be increasing given the annual trends,
no completely reported year exceeded 25% utilization
across the 17 sites. Further compounding this low utilization is the fact that these 17 sites are academic centers in
which the evidence for IVC is theoretically better known
than in the community setting. Further studies will be necessary to evaluate utilization of IVC outside of high-volume
academic centers.

452.e20

It is interesting to note that utilization of IVC is lower in
European centers, relative to United States and Asian institutions. The reasons for this are somewhat unclear, given
the EAU recommendations appear to be the catalyst for initiation of IVC use. ODMIT-C [12] was conducted across 46
centers in Great Britain and no British institutions, which
may have had experience in the trial phase, are included in
this multi-center analysis, potentially skewing the European
numbers. It is difficult to assess whether there are healthcare system-specific factors hindering European centers
from widespread adoption of IVC. Further investigations
are needed to further evaluate the role of systemic barriers
to IVC administration. It should be noted, however, that our
understanding of regional disparities in IVC utilization is
limited by institutional variability in usage. For example,
one Asian center reported 93% utilization of IVC while
another noted 0%. Therefore, some of the found regional
differences may in fact be driven by institutional practices
of participating centers rather than by geographic factors.
Among the entire cohort, the reason utilization rates lag
may in large part pertain to concerns over extravasation of
chemotherapeutic agents. Such leakage associated with the
bladder cuff cystotomy is one of the more often discussed
reasons why the treatment may be avoided [17]. While no
increased length of stay or 30-day readmission rate was
observed in our study with administration of IVC, there are
reports in the bladder cancer literature that extravasation of
chemotherapeutic agents may cause severe effects −
including necrosis, inflammation, and ulceration of the
bladder and surrounding tissue [19]. Also, given the relatively high ECOG scores of the patient population (no
ECOG 0 patients included), perceived frailty in the context
of perceived harms may have contributed to lower utilization of IVC.
That said, multiple studies in the non-muscle invasive
bladder cancer literature for both gemcitabine and mitomycin C administration have demonstrated comparable rates
of adverse events among those who receive perioperative
intravesical chemotherapy and placebo [20,21]. Its use has
also been demonstrated safe in the minimally invasive
RNU setting [22]. Despite this favorable safety profile, utilization of postoperative IVC in the non-muscle invasive
bladder cancer setting is also low [23,24].
Survey data in the UTUC setting indicated that some
urologists avoided treatment on account of a theoretical
risk of leak after RNU and extravasation of chemotherapy
and 12% indicated that they did not use IVC for fear of
overtreatment [17]. A perforation is notably a steadfast contraindication to IVC following transurethral resection of
bladder tumor [25]. It is possible the risk of extravasation
explains decreased utilization of IVC among older patients
in our study, as they may be presumed less likely to heal a
new cystotomy. The evidence, however, suggests that even
in the setting of a RNU this concern is overstated. Moriarty
et al. evaluated a cohort of 51 patients who received intraoperative IVC with mitomcyin C (n = 48) and adriamycin
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(n = 3), the majority of whom had an extravesical bladder
cuff taken, and found that none of these patients had
complications attributable to intravesical chemotherapy
administration [26]. The ODMIT-C trial similarly reported
no adverse events related to postoperative IVC administration and the majority of these patients had a formal bladder
cuff excision [12].
Various administration approaches have been studied to
see if alternate modes of administration with timing, toxicity, or cost-benefits could provide a path to more widespread use of the practice. Freifeld et al. examined
intraoperative vs. postoperative administration of mitomycin C and gemcitabine and demonstrated the efficacy of
intraoperative IVC, as well as the safety and efficacy of
gemcitabine in this setting [27]. A currently-enrolling prospective trial is examining the use of intraoperative intravesical gemcitabine as well [28]. Studies from the nonmuscle invasive bladder cancer literature have demonstrated a high level of efficacy and favorable safety profile
for gemcitabine in preventing bladder recurrence of urothelial carcinoma, as well as a favorable cost relative to mitomycin C [20,29]. Other studies have questioned the need
for chemotherapeutic agents at all. Yamamoto et al. investigated the use of intravesical sterile water continuous bladder irrigation at the time of nephroureterectomy and
demonstrated a significant reduction in intravesical recurrence, consistent with previously reported improvements
with postoperative IVC. It is possible that use of gemcitabine or sterile water, given reduced toxicity and cost relative to mitomycin C and pirarubicin, and intraoperative
timing of IVC could increase utilization of IVC in the
future. Due to limitations of multi-institutional data reporting, our study was unable to analyze the timing of IVC
administration.
IVC use was noted to be increased among those who
underwent laparoscopic, rather than robotic RNU. The clinical significance of this finding is unclear. Perhaps centers
which preferentially perform laparoscopic RNU tend to
also favor IVC use. It is possible that the increased receipt
of IVC among those who underwent laparoscopic approach
is related to the fact that significantly more patients who
underwent the laparoscopic approach had endoscopic management of the bladder cuff, which was strongly associated
with use of IVC. This is a logical association, as it makes
sense that fears of IVC toxicity might be lowered without a
fresh open cystotomy and given the logistical ease of instilling chemotherapy while already accessing the bladder in a
retrograde fashion. Given recent analysis demonstrating
increased intravesical recurrence with endoscopic management of the bladder cuff [30], it is clear that this approach
to the bladder cuff is not the preferred management. Our
findings merely indicate an association between the practice
and IVC use.
One particular data trend in the multivariable analysis
lends itself to interesting hypothesis generation. There was
a trend toward decreased use of IVC in those who

underwent neoadjuvant chemotherapy. ECOG 8141 demonstrated a 14% pathological complete response rate to neoadjuvant chemotherapy in UTUC, as well as significant
downstaging of invasive disease [31]. It is possible that
some practitioners believe the utility of IVC is decreased in
the setting of systemic chemotherapeutic agent administration, particularly in light of level-1 evidence for administration of adjuvant systemic chemotherapy [32].
Our cohort includes only patients who underwent minimally invasive (laparoscopic or robotic) nephroureterectomy. Over the past decade, minimally invasive
nephroureterectomy has become a more popular surgical
approach to the treatment of UTUC [33,34]. Multiple studies have demonstrated oncologic comparability between
open and minimally invasive techniques, although there is
some debate about the optimal surgical approach in cases
of higher stage disease [8,35,36]. Our study is unable to
address the effect of a minimally invasive RNU relative to
open RNU on IVC administration, due to its limited inclusion criteria.
This study does not attempt to evaluate rates of intravesical recurrence, as stratified by IVC usage. Multiple randomized-control trials have demonstrated the benefit of IVC use
[12,13]. Given poorly matched IVC and non-IVC cohorts
and the presence of numerous confounders, we felt that
attempts to draw conclusions about the efficacy of IVC
administration from these data would not yield clinically
meaningful conclusions.
There are a number of other limitations to our study.
Given the multi-institutional nature of the database, it is
possible that non-reporting of IVC administration could
bias the overall percentage of IVC administered, as some
centers regularly utilize this practice, while others less so.
Regardless, even if exclusions were not carried out and all
excluded cases assumed to have used IVC, IVC use would
remain lower than previously estimated values. Also, our
study does not have the granularity to determine postoperative vs. intraoperative intravesical chemotherapy, so our
findings represent a combination of those 2 interventions as
“perioperative” IVC. While preliminary literature shows
there may be some equivalence between these practices,
high-level data demonstrating that is still pending. There is
also no data on the choice of chemotherapeutic agent.
Another limitation of our study is that certain study sties’
practice patterns may skew our results. For example, certain
sites in Asia had extremely high rates of IVC use. Therefore, it is possible that the observation that utilization was
much higher in Asia than other regions may be a reflection
of individual sites’ practice patterns rather than true geographic differences.
5. Conclusions
Despite guideline recommendations and level 1 evidence, use of perioperative IVC at time of RNU remains
lower than previously estimated. Use within European
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centers is particularly low. Older patients are less likely to
receive the intervention, despite limited demonstrated
toxicity. Further studies are necessary to determine if alterations in timing of IVC or chemotherapeutic agent will provide equivalent oncologic efficacy and increased utilization
of perioperative IVC.
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